2025 Q4 -tulosraportti
14 päivää sitten
‧39 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 644 | NON | SWB | ||
| 1 500 | NON | SWB | ||
| 360 | NON | SWB | ||
| 1 390 | NON | SWB | ||
| 857 | NON | SWB |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 31 664 | 22 880 | +8 784 | 18 696 |
| Nordea Bank Abp | 4 028 | 650 | +3 378 | 0 |
| Avanza Bank AB | 1 720 | 858 | +862 | 0 |
| Skandinaviska Enskilda Banken AB | 703 | 417 | +286 | 0 |
| SSW Market Making GmbH | 17 | 733 | −716 | 0 |
| Danske Bank A/S | 2 560 | 4 066 | −1 506 | 66 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Swedbank AB | 0 | 11 088 | −11 088 | 0 |
| Danske Bank A/S | 2 560 | 4 066 | −1 506 | 66 |
| SSW Market Making GmbH | 17 | 733 | −716 | 0 |
| Skandinaviska Enskilda Banken AB | 703 | 417 | +286 | 0 |
| Avanza Bank AB | 1 720 | 858 | +862 | 0 |
| Nordea Bank Abp | 4 028 | 650 | +3 378 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·31 min sittenNow that it's a bit quiet in here, it would be fun to hear which stocks you otherwise hold or see potential in going forward 😊 I personally bought into the following a few weeks ago, which I find very exciting: Circio as well as Ascelia Pharma·10 min sittenCool.. It's always exciting to hear what others have in their portfolio and check it out 😊
·4 t sittenwhy is it falling
·2 t sittenWhy is it rising? ;) NOTE irony. A stock both falls and rises in intervals for no reason at all sometimes and that is completely normal. The basic principle is supply and demand. Market psychology plays a role. News and rumors can make the stock both rise and fall. In Curasight's case, it could be the debt conversion that affects it a little (dilution). Look at a stock long-term to get an idea of movements. This will be my short answer- ·1 päivä sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
·2 päivää sittenWhen one looks at available trades, there are constantly 4000 shares cycling between the highest price and a bit cheaper, respectively, first on the sell side, then conversely on the buy side. Is it a bot that just constantly day trades? There is currently approx. 4% difference between sell and buy. So one could well imagine that a bot optimizes on buy/sell? Is that perhaps the case?
·2 päivää sittenSee or rewatch CSO Andreas Kjær's presentation in connection with the .TD Cowen conference from last week: Andreas Kjær reviews the case, preliminary data, competitive situation/market potential, patent protection, timeline towards 2029 etc.. The presentation gives a very good all-round picture of where the company is (wishes to be) headed. Together with CSO Andreas Kjær and CEO Ulrich Krasilnikoff, Jesper M. Lange, Senior Executive Advisor from Gorrisen Federspiel, also participated. Jesper M. Lange describes himself as follows on his LinkedIn profile: "I bring a unique combination of business and legal acumen, with a proven track record in both executive advisory and CEO leadership roles. At Gorrissen Federspiel my role is to assist biotech and pharma companies with (non-legal) strategy and operational execution in the preparation of significant inflection points and transactions (VC-funding, M&A, IPO, licensing, strategic partnerships, Growth funding etc.)." https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/ibNkhKEwKtK7iUrQ6v5xFB?fbclid=IwY2xjawQc3QRleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeIfTCMrDXDhA8I7gurKclQZWaXIPo1qTI_clnUdUoMU8q2FtMzlj1sghi6cM_aem_nZnpxwzD3WHTXwOXAclVEg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
14 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·31 min sittenNow that it's a bit quiet in here, it would be fun to hear which stocks you otherwise hold or see potential in going forward 😊 I personally bought into the following a few weeks ago, which I find very exciting: Circio as well as Ascelia Pharma·10 min sittenCool.. It's always exciting to hear what others have in their portfolio and check it out 😊
- ·4 t sittenwhy is it falling·2 t sittenWhy is it rising? ;) NOTE irony. A stock both falls and rises in intervals for no reason at all sometimes and that is completely normal. The basic principle is supply and demand. Market psychology plays a role. News and rumors can make the stock both rise and fall. In Curasight's case, it could be the debt conversion that affects it a little (dilution). Look at a stock long-term to get an idea of movements. This will be my short answer
- ·1 päivä sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
- ·2 päivää sittenWhen one looks at available trades, there are constantly 4000 shares cycling between the highest price and a bit cheaper, respectively, first on the sell side, then conversely on the buy side. Is it a bot that just constantly day trades? There is currently approx. 4% difference between sell and buy. So one could well imagine that a bot optimizes on buy/sell? Is that perhaps the case?
- ·2 päivää sittenSee or rewatch CSO Andreas Kjær's presentation in connection with the .TD Cowen conference from last week: Andreas Kjær reviews the case, preliminary data, competitive situation/market potential, patent protection, timeline towards 2029 etc.. The presentation gives a very good all-round picture of where the company is (wishes to be) headed. Together with CSO Andreas Kjær and CEO Ulrich Krasilnikoff, Jesper M. Lange, Senior Executive Advisor from Gorrisen Federspiel, also participated. Jesper M. Lange describes himself as follows on his LinkedIn profile: "I bring a unique combination of business and legal acumen, with a proven track record in both executive advisory and CEO leadership roles. At Gorrissen Federspiel my role is to assist biotech and pharma companies with (non-legal) strategy and operational execution in the preparation of significant inflection points and transactions (VC-funding, M&A, IPO, licensing, strategic partnerships, Growth funding etc.)." https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/ibNkhKEwKtK7iUrQ6v5xFB?fbclid=IwY2xjawQc3QRleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeIfTCMrDXDhA8I7gurKclQZWaXIPo1qTI_clnUdUoMU8q2FtMzlj1sghi6cM_aem_nZnpxwzD3WHTXwOXAclVEg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 644 | NON | SWB | ||
| 1 500 | NON | SWB | ||
| 360 | NON | SWB | ||
| 1 390 | NON | SWB | ||
| 857 | NON | SWB |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 31 664 | 22 880 | +8 784 | 18 696 |
| Nordea Bank Abp | 4 028 | 650 | +3 378 | 0 |
| Avanza Bank AB | 1 720 | 858 | +862 | 0 |
| Skandinaviska Enskilda Banken AB | 703 | 417 | +286 | 0 |
| SSW Market Making GmbH | 17 | 733 | −716 | 0 |
| Danske Bank A/S | 2 560 | 4 066 | −1 506 | 66 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Swedbank AB | 0 | 11 088 | −11 088 | 0 |
| Danske Bank A/S | 2 560 | 4 066 | −1 506 | 66 |
| SSW Market Making GmbH | 17 | 733 | −716 | 0 |
| Skandinaviska Enskilda Banken AB | 703 | 417 | +286 | 0 |
| Avanza Bank AB | 1 720 | 858 | +862 | 0 |
| Nordea Bank Abp | 4 028 | 650 | +3 378 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
14 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·31 min sittenNow that it's a bit quiet in here, it would be fun to hear which stocks you otherwise hold or see potential in going forward 😊 I personally bought into the following a few weeks ago, which I find very exciting: Circio as well as Ascelia Pharma·10 min sittenCool.. It's always exciting to hear what others have in their portfolio and check it out 😊
- ·4 t sittenwhy is it falling·2 t sittenWhy is it rising? ;) NOTE irony. A stock both falls and rises in intervals for no reason at all sometimes and that is completely normal. The basic principle is supply and demand. Market psychology plays a role. News and rumors can make the stock both rise and fall. In Curasight's case, it could be the debt conversion that affects it a little (dilution). Look at a stock long-term to get an idea of movements. This will be my short answer
- ·1 päivä sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
- ·2 päivää sittenWhen one looks at available trades, there are constantly 4000 shares cycling between the highest price and a bit cheaper, respectively, first on the sell side, then conversely on the buy side. Is it a bot that just constantly day trades? There is currently approx. 4% difference between sell and buy. So one could well imagine that a bot optimizes on buy/sell? Is that perhaps the case?
- ·2 päivää sittenSee or rewatch CSO Andreas Kjær's presentation in connection with the .TD Cowen conference from last week: Andreas Kjær reviews the case, preliminary data, competitive situation/market potential, patent protection, timeline towards 2029 etc.. The presentation gives a very good all-round picture of where the company is (wishes to be) headed. Together with CSO Andreas Kjær and CEO Ulrich Krasilnikoff, Jesper M. Lange, Senior Executive Advisor from Gorrisen Federspiel, also participated. Jesper M. Lange describes himself as follows on his LinkedIn profile: "I bring a unique combination of business and legal acumen, with a proven track record in both executive advisory and CEO leadership roles. At Gorrissen Federspiel my role is to assist biotech and pharma companies with (non-legal) strategy and operational execution in the preparation of significant inflection points and transactions (VC-funding, M&A, IPO, licensing, strategic partnerships, Growth funding etc.)." https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/ibNkhKEwKtK7iUrQ6v5xFB?fbclid=IwY2xjawQc3QRleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeIfTCMrDXDhA8I7gurKclQZWaXIPo1qTI_clnUdUoMU8q2FtMzlj1sghi6cM_aem_nZnpxwzD3WHTXwOXAclVEg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 644 | NON | SWB | ||
| 1 500 | NON | SWB | ||
| 360 | NON | SWB | ||
| 1 390 | NON | SWB | ||
| 857 | NON | SWB |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 31 664 | 22 880 | +8 784 | 18 696 |
| Nordea Bank Abp | 4 028 | 650 | +3 378 | 0 |
| Avanza Bank AB | 1 720 | 858 | +862 | 0 |
| Skandinaviska Enskilda Banken AB | 703 | 417 | +286 | 0 |
| SSW Market Making GmbH | 17 | 733 | −716 | 0 |
| Danske Bank A/S | 2 560 | 4 066 | −1 506 | 66 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Swedbank AB | 0 | 11 088 | −11 088 | 0 |
| Danske Bank A/S | 2 560 | 4 066 | −1 506 | 66 |
| SSW Market Making GmbH | 17 | 733 | −716 | 0 |
| Skandinaviska Enskilda Banken AB | 703 | 417 | +286 | 0 |
| Avanza Bank AB | 1 720 | 858 | +862 | 0 |
| Nordea Bank Abp | 4 028 | 650 | +3 378 | 0 |